UCB (UCB.VI) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

UCB.VI · Stock Price

EUR 235.30+80.20 (+51.71%)

Market Cap: $52.5B

Historical price data

Market Cap: $52.5BPipeline: 200 drugs (167 Phase 3)Patents: 20Founded: 1928Employees: 9,000+HQ: Brussels, Belgium

Sector Ranking#47 in Biologics / Biosimilars #3 in Neuroscience & CNS

Overview

UCB is a mission-driven, global biopharmaceutical company dedicated to improving the lives of patients with severe diseases in neurology and immunology. The company has achieved a successful strategic transformation, now boasting a market capitalization of approximately $48.3 billion, a commercial portfolio including key products like bimekizumab, and a deep, late-stage pipeline of 609 candidates. Its strategy is anchored in patient-inspired science, a sophisticated technology platform for antibody and biomarker discovery, and a commitment to sustainable growth through internal R&D and strategic external innovation.

NeurologyImmunology

Technology Platform

Integrated platform combining patient-inspired translational science for biomarker discovery, advanced monoclonal antibody engineering (including dual-targeting and FcRn inhibitors), and patient-centric clinical development.

Pipeline

200

200 drugs in pipeline167 in Phase 3

Drug	Indication	Stage
Certolizumab Pegol	Rheumatoid Arthritis	Phase 3
USL261 + Placebo	Epilepsy	Phase 3
Certolizumab pegol	Rheumatoid Arthritis	Phase 3
Placebo + Brivaracetam + Brivaracetam + Antiepileptic drugs ...	Epilepsy	Phase 3
Lacosamide	Epilepsy	Phase 3

Funding History

1

Total raised:$1.2B

Debt$1.2BUndisclosedMay 15, 2020

FDA Approved Drugs

18

KYGEVVINDANov 3, 2025

ZILBRYSQNDAOct 17, 2023

BIMZELXBLAOct 17, 2023

Opportunities

Significant near-term growth from label expansions of core assets (bimekizumab, rozanolixizumab) into new autoimmune and neurological indications.

Long-term opportunity lies in the vast early-stage pipeline of 609 candidates and leveraging the technology platform for next-generation therapies.

Risk Factors

High clinical and commercial execution risk in intensely competitive markets (Immunology/Neurology).

Pipeline growth is dependent on successful trial outcomes for key late-stage programs.

Faces ongoing pricing and reimbursement pressures globally.

Competitive Landscape

Faces intense competition from large pharma (J&J, Novartis, AbbVie) and biotech peers in both immunology (IL-17/IL-23 inhibitors) and neurology (FcRn inhibitors). Competes on the basis of scientific differentiation (e.g., dual cytokine inhibition), patient-centric development, and deep therapeutic area expertise.